MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a preventive antibody-based therapy for influenza. The agreement – first ...

At the 2026 J.P Morgan Healthcare Conference, MSD’s (Merck & Co) CEO, Robert Davis, laid out the company’s plans to derisk its future sales amid the looming loss of Keytruda’s market exclusivity.

MSD declines to exercise option for EVX-B2 development Evaxion is now able to out-license EVX-B2 to another partner Evaxion maintains its strong belief in EVX-B2, which has shown to be protective ...

Merck Sharp & Dohme (MSD) has agreed to acquire Cidara Therapeutics in a transaction valued at approximately $9.2 billion, following encouraging results from the company’s phase 2b trial of its lead ...

Unlike vaccines, Cidara’s products do not rely on the immune system. Credit: Andy Dean Photography via Shutterstock.com. MSD has agreed to acquire Cidara Therapeutics in a $9.2bn deal, adding a new ...

Abstract: The design of full programmable type-2 membership function circuit is presented in this paper. This circuit is used to implement the fuzzifier block of Type-2 Fuzzy Logic Controller chip. In ...

Main Street Duncan has announced a partnership with Leadership Duncan Class 30 to change the city's Christmas parade route back to the traditional route. MSD said in a press release that due to “lack ...

TL;DR: HP's new HyperX audio lineup features the premium Cloud Alpha 2 Wireless headset with pro-grade sound, 250-hour battery life, and dual Bluetooth/2.4 GHz connectivity. The affordable Cloud ...

The Ministry of Social Development’s Te Pae Tawhiti transformation has moved fully into its delivery phase with refreshed management and governance structures to ensure effective oversight and risk ...

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA ® (pembrolizumab) is MSD's anti-PD-1 therapy. ATG-022 is uniquely positioned in the global landscape, with data supporting ...